

**RESTRICTED VETERINARY MEDICINE**  
**Keep out of reach of children**  
**FOR ANIMAL TREATMENT ONLY**

# **Cobactan<sup>®</sup> LC**

**For the treatment of clinical mastitis in lactating cows**

## **Active Ingredient:**

9.375mg/g Cefquinome (as sulphate). Each syringe contains 75mg Cefquinome.

**15 syringes**

## **Presentation**

An intramammary infusion in paraffin for rapid release and elimination containing 9.375mg/g cefquinome (as sulphate). One syringe contains 75mg cefquinome. Presented as a pack of 15 syringes and 15 teat wipes.

## **Indications**

For the treatment of clinical mastitis in lactating cows caused by *Staphylococcus aureus*, *Streptococcus uberis*, *Streptococcus dysgalactiae*, *Escherichia coli* and other enterobacteria susceptible to cefquinome.

## **Dosage and administration**

Milk out the affected quarter(s). After thoroughly cleaning and disinfecting the teat and teat orifice, infuse the contents of one syringe into each affected quarter. Disperse the product by gently massaging the teat and udder of the affected animal. Treat the teat canal of the infected quarter(s) every 12 hours, i.e. after each of 3 successive milkings. Use each syringe for the treatment of only one teat.

## **Contraindication**

Not to be administered to animals which are known to be hypersensitive to cefquinome.

## **Withholding Period**

**It is an offence for users of this product to cause residues exceeding the relevant MRL in the New Zealand (Maximum Residues Limits of Agricultural Compounds) Food Standards.**

**Meat:** Cattle producing meat or offal for human consumption must not be sold for slaughter either during treatment or within 2 days of the last treatment.

**Milk:** Milk intended for sale for human consumption must be discarded during treatment and for not less than 7 milkings or approximately 84 hours following the last treatment.

## Handling precautions

Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross sensitivity to cephalosporin and vice versa. Allergic reactions to these substances may occasionally be serious.

1. Do not handle this product if you know you are sensitised, or if you have been advised not to work with such preparations.
2. Handle this product with great care to avoid exposure, taking all recommended precautions.
3. If you develop symptoms following exposure, such as skin rash, you should seek medical advice and show the Doctor this warning. Swelling of the face, lips or eyes or difficulty in breathing are more serious symptoms and require urgent medical attention.

## FURTHER INFORMATION

*In vitro*, cefquinome has antibiotic activity against common bacteria including:

Gram-positive: *Staphylococcus aureus*, *Streptococcus dysgalactiae*, *Streptococcus uberis* and *Corynebacterium pyogenes*.

Gram-negative: *Salmonella spp.*, *Escherichia coli*, *Actinobacillus pleuropneumoniae*, *Haemophilus spp.*, *Pasteurella spp.*, *Klebsiella spp.* and *Proteus mirabilis*.

- Indiscriminate use of the product could contribute to the development of antibiotic resistance. The product should only be used in individual cases of serious infections that are not likely to respond to any other antibiotic.
- The product must not be used to treat groups of food-producing animals unless bacteriology (prospectively or retrospectively) has confirmed the diagnosis and sensitivity tests have shown that it is the only alternative that is likely to be effective.
- The prescribing veterinarian must notify the ACVM group of every case the antibiotic is prescribed giving date, species prescribed for and condition treated.

## Storage

Store below 25°C.

ACVM Registration No. A8116.

See [www.nzfsa.govt.nz/acvm/](http://www.nzfsa.govt.nz/acvm/) for registration conditions.

Registered to:

Schering-Plough Animal Health Ltd

33 Whakatiki Street, Upper Hutt, NZ

Phone: 0800 800 543

[www.msd-animal-health.co.nz](http://www.msd-animal-health.co.nz)

